Abstract
Oral cancer, predominantly oral squamous cell carcinoma (OSCC), poses a significant global health problem with high mortality rates largely attributed to late-stage diagnosis. Traditional diagnostic methods, such as visual inspection and tissue biopsy, have limitations such as subjective interpre-tation, invasiveness, and limited sensitivity for early-stage lesions. Artificial intelligence (AI) has transformative potential to overcome these limitations. It is proposed that AI-powered methods can increase diagnostic accuracy, facilitate early diagnosis, and improve patient prognoses by fa-cilitating access to expert-level screening. The chapter systematically examines AI applications across three diagnostic domains. In imaging-based screening, deep learning algorithms analyze clinical, radiographic, and microscopic images, achieving sensitivities of 90-95% for detecting malignant lesions, often surpassing human performance. Techniques like automated analysis of fluorescent images and confocal laser endomicroscopy enable non-invasive, real-time identifica-tion of neoplastic tissue. In histopathological screening, Whole-Slide Imaging (WSI) digitizes tis-sue specimens, allowing Convolutional Neural Networks (CNNs) to quantitatively assess cytological and architectural atypia. This automates the detection of OSCC and tumor microenvi-ronment features, enhancing objectivity and reproducibility. Furthermore, AI-driven biomarker discovery utilizes machine learning models, including Support Vector Machines and Random Forests, to interrogate high-dimensional genomic, proteomic, and clinical data. This facilitates the identification of predictive biomarkers for risk stratification and early diagnosis. The integration of these AI systems offers substantial benefits, including operational efficiency through automated analysis, accelerated diagnostic timelines, and the potential for deployment in low-resource settings to bridge healthcare disparities. However, the translation of these technologies into clinical prac-tice faces significant challenges. These include the dependency on large, curated, and diverse datasets for training, concerns regarding algorithmic generalizability across populations, and the "black box" nature of complex models that impedes interpretability. Ethical and regulatory frame-works concerning data privacy, algorithmic bias, and liability require further development. In con-clusion, AI-assisted screening demonstrates significant efficacy for the early and accurate detection of OSCC in oral oncology. The synergistic application of AI in image analysis, digital pathology, and biomarker discovery has the potential to standardize diagnoses and improve accessibility. However, the full integration of these tools into clinical practice depends on overcoming current challenges related to data quality, model validation, and ethical governance. Future research should prioritize large-scale, multicenter studies and the development of transparent, robust AI systems to realize their promise of improving clinical decision-making and patient outcomes.